Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition.

Autor: Kay KE; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Lee J; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Hong ES; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Beilis J; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Dayal S; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Wesley ER; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Mitchell S; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Wang SZ; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Silver DJ; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Volovetz J; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Johnson S; Rose Ella Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, United States of America., McGraw M; Rose Ella Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, United States of America., Grabowski M; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Lu T; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Freytag L; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Narayana VK; Metabolomics Australia, The University of Melbourne, Melbourne, Australia., Freytag S; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Best SA; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Whittle JR; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Wang Z; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Reizes O; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Yu JS; Department of Cancer Biology, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Hazen SL; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Brown JM; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Bayik D; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America., Lathia J; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute Cleveland Clinic, Cleveland, United States of America.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.